Dermatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

iTRAQ-based proteomic identification of leucine rich alpha 2 glycoprotein (LRG) as a novel inflammatory biomarker in autoimmune diseases
Annals of Rheumatic Diseases, 11/09/09

Satoshi Serada et al. – LRG represents a novel serum biomarker for monitoring disease activity during therapy in autoimmune patients, particularly useful in patients with active disease but normal CRP levels. Therefore, serum LRG potentially surrogate for CRP.

Methods

Sera obtained from RA patients before and after anti-TNF therapy were analyzed by quantitative proteomics using isobaric tags for relative and absolute quantitation (iTRAQ) and further validated by ELISA.

Results

326 proteins identified by proteomic analysis
Identified increased serum levels of leucine rich alpha 2 glycoprotein (LRG) in RA patients before therapy
ELISA analysis revealed serum LRG concentrations significantly elevated in RA patients compared to healthy controls and decreased after anti-TNF therapy
Serum LRG concentrations correlated with serum C-reactive protein (CRP) levels in patients with RA, Behcet’s disease and Crohn’s disease (CD) and correlated with disease activity in RA and CD
In subpopulation of active CD patients with normal CRP levels, serum LRG concentrations elevated
Serum LRG concentrations were significantly higher in CD patients refractory to anti-TNF therapy compared to those responsive to therapy